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Advanced colorectal polyps with the molecular and morphological features of serrated polyps
and adenomas: concept of a ‘fusion’ pathway to colorectal cancer
Aim: To establish and explain the pattern of molecular
signatures across colorectal polyps.
Methods and results: Thirty-two sessile serrated aden-
omas (SSA), 10 mixed polyps (MP), 15 traditional
serrated adenomas (SA), 49 hyperplastic polyps (HP)
and 84 adenomas were assessed for mutation of KRAS
and BRAF and aberrant expression of p53. The ﬁndings
were correlated with loss of expression of O-6-methyl-
guanine DNA methyltransferase (MGMT). KRAS muta-
tion occurred more frequently (26.5%) than BRAF
mutation (4.8%) in adenomas (P<0.001) and partic-
ularly in adenomas with villous architecture (50%).
Loss of expression of MGMT correlated with KRAS
mutation in small tubular adenomas (P<0.04). BRAF
mutation was frequent in HPs (67%) and SSAs (81%),
while KRAS mutation was infrequent (4% and 3%,
respectively). Of MPs and SAs, 72% had either BRAF
or KRAS mutation. Aberrant expression of p53 was
uncommon overall, but occurred more frequently in
MPs and SAs (12%) than adenomas (1%) (P<0.04)
and there was concordant loss of expression of MGMT.
Conclusions: Molecular alterations that are character-
istic of the serrated pathway and adenoma–carcinoma
sequence can co-occur in a minority of advan-
ced colorectal polyps that then show morphological
features of both pathways. These lesions account for
only 2% of colorectal polyps, but may be relatively
aggressive.
Keywords: adenoma, colon, hyperplastic, polyp, serrated
Abbreviations: CRC, colorectal cancer; HP, hyperplastic polyp; MGMT, O-6-methylguanine DNA methyltransferase;
MP, mixed polyp; SA, serrated adenoma; SSA, sessile serrated adenoma; TA, tubular adenoma; TVA, tubulo-villous
adenoma; VA, villous adenoma
Introduction
The traditional view of epithelial polyps of the colorec-
tum envisages a larger non-neoplastic category of
hyperplastic polyps (HPs) that can be safely ignored
and a smaller category of neoplastic polyps or aden-
omas that are precancerous.
1 With respect to aden-
omas, it is clear that the majority will not progress
to colorectal cancer (CRC).
2 The risk of cancer develop-
ing within an adenoma increases with size, grade of
dysplasia (synonymous with intraepithelial neoplasia)
and villosity.
3 These features, together with polyp
numbers, are also predictive of metachronous neopla-
sia and may therefore inﬂuence the decision to offer
follow-up endoscopic surveillance.
4 However, the
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villous change may not be fully reproducible and it
may be difﬁcult to distinguish new from recurrent
adenomas. Establishing a risk proﬁle on the basis of the
traditional features of adenoma is therefore not always
straightforward.
The addition of molecular proﬁling to polyp
description offers hope of a more objective and
therefore reproducible approach to the classiﬁcation
of colorectal adenomas. The genetic evolutionary
paradigm envisages a linear sequence of changes
beginning with bi-allelic inactivation of APC, followed
by oncogenic KRAS mutation and culminating in
inactivation of TP53 at the transition from adenoma
to carcinoma.
5 While there is good evidence that
KRAS mutation is associated with advanced adenoma
features
6 and could therefore be used as objective
evidence of aggression, this approach has a number
of limitations. First, KRAS mutation also occurs
frequently in dysplastic aberrant crypt foci (micro-
adenomas) and in some small tubular adenomas,
suggesting that KRAS mutation may initiate a subset
of small adenomas with limited potential for progres-
sion.
6,7 Second, around 70% of CRCs lack mutation
of KRAS.
8 From this it follows that most of the
precancerous lesions that eventually become cancers
do not in fact have KRAS mutation. There is
increasing evidence that CRC evolves through a
number of pathways and the traditional adenoma–
carcinoma sequence, with its accompanying genetic
steps, provides a surprisingly narrow window of
understanding of this multipathway reality.
9
In recent years, the fundamental division of colorec-
tal polyps into precancerous adenomas and innocent
HPs has begun to erode and the concept of an
alternative serrated pathway has gained support. This
revision began with the description of an intermediate
lesion described as serrated adenoma (SA).
10 Initially,
however, SA was not conceived as an intermediate
category of polyp but essentially as an adenoma with a
superimposed serrated architecture that conferred only
a superﬁcial likeness to a HP.
10 Additionally, the mixed
polyp (MP) was perceived as a chance collision between
a HP and an adenoma, giving a combined polyp. These
preliminary interpretations did not represent a major
departure from the traditional classiﬁcation of colorec-
tal polyps but preserved the fundamental distinction of
neoplastic adenomas versus non-neoplastic HPs.
Subsequently, it was argued that HP and SA are
related lesions.
11 The latter could arise within the
former (giving a MP) or could develop as de novo
SA but through mechanisms shared with HPs.
This proposal subsequently received strong support
through the demonstration of molecular alterations
common to both types of serrated polyp, notably
mutation of BRAF and extensive DNA methylation.
12
This viewpoint was consolidated through the formal
recognition of two largely independent pathways of
colorectal tumorigenesis: (i) the traditional adenoma–
carcinoma sequence associated with chomosomally
unstable CRCs,
13 and (ii) the ‘serrated pathway’
culminating in CRCs with DNA microsatellite insta-
bility (MSI), mutation of BRAF and extensive DNA
methylation.
12,14–20
This paper explores the possibility that the early
evolution of colorectal cancer is not limited to two
essentially independent pathways, but often combines
components of these pathways. Indeed, the successful
‘fusion’ of the hyperproliferation and crypt ﬁssion that
characterize adenomas
21 with the inhibition of apop-
tosis that has been linked with serrated polyps
22,23 may
generate lesions with enhanced aggressiveness. Specif-
ically, it is suggested that methylation of the DNA
repair gene O-6-methylguanine DNA methyltransferase
(MGMT), mutation of KRAS and inactivation of TP53
provide critical combinations of molecular ‘cross-over’
between the two pathways that occur at the stage of
precancerous polyps.
Materials and methods
tissues
The colorectal polyps used in this study were from a
previously characterized subset of a consecutive series of
1250 colonoscopically derived lesions.
24 The study
group included all SAs (sessile and traditional) and
MPs and a subset of conventional adenomas and HPs.
The previous study analysed proliferative indices and
there was therefore selection of HPs that were large and
well-oriented and likely to provide sufﬁcient numbers of
longitudinally sectioned crypts. Polyps were eliminated
from the present study if there was insufﬁcient residual
tissue, blocks contained more than one polyp, polyps
contained foci of invasive cancer, or there was failure
of DNA ampliﬁcation for both the BRAF and KRAS
mutation assays. Fifteen additional polyps from the
parent series generated a total study group of 190
polyps. These were reviewed by the ﬁrst author and
classiﬁed as: HPs (n ¼ 49), tubular adenomas (TAs)
(n ¼ 62), tubulovillous and villous adenomas (TVAs ⁄
VAs) (n ¼ 22), sessile SAs (SSAs) (n ¼ 32), MPs (n ¼
10) and traditional SAs (n ¼ 15). SSA has also been
termed sessile serrated polyp and serrated polyp with
atypical proliferation.
17,25–27 SSA is distinguished from
HP on the basis of greater size, aberrant architecture,
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dilection for proximal colon
25 and molecular features
including a higher frequency of BRAF mutation and
more extensive DNA methylation.
14,16,17 However, the
combination of architectural and cytological changes is
insufﬁcient for a diagnosis of dysplasia. Serrated polyps
with dysplasia include MPs and SAs. MPs may be
conceived as a combined lesion that includes: (i) a
serrated component that is non-dysplastic and resem-
blesHPorSSA,and(ii)adysplasticcomponentthatmay
resemble either SA or conventional adenoma.
28 For the
purposes of this study, lesions were also included as MPs
if they comprised separate serrated and non-serrated
components that were both dysplastic. SAs are homo-
geneous lesions in which there is epithelial serration
reminiscent of a HP or SSA together with architectural
and cytological changes warranting a diagnosis of
dysplasia. The cytological atypia of SA may appear
similar to that of conventional adenoma in which
nuclei are elongated, hyperchromatic and pseudo-
stratiﬁed. However, some SAs may be characterized by
non-adenomatous forms of dysplasia in which the
nuclei are enlarged, ovoid, vesicular and contain a
prominent nucleolus, while the cytoplasm is relatively
abundant and eosinophilic. The anatomical site of
polyps was grouped as proximal colon (up to splenic
ﬂexure) versus distal colon and rectum combined. The
studywasapprovedbytheInstitutional Review Boardof
the Faculty of Medicine, McGill University.
dna extraction
Genomic DNA was extracted from archival parafﬁn-
embedded tissue sections using DNeasy Tissue Kit
(Qiagen, Hilden, Germany) according to the manufac-
turer’s instructions except for the omission of xylene
treatment. Brieﬂy, ﬁve 4-lm non-microdissected sec-
tions (polyps were generally accompanied by little
normal mucosa) and 180 ll of ATL buffer were
dissolved at 80 C and then digested overnight with
20 ll of proteinase K at 55 C. Following centrifugation
at 2000 r.p.m. (300 g) for 5 min, the lower phase was
applied to a DNeasy tissue column. Bound DNA was
washed by centrifugation through ethanol and then
eluted from the column using AE buffer.
kras and braf mutations
KRAS mutation analysis at codons 12 and 13 was
performed using direct automated sequencing of a
fragment containing codon 12 and 13 in exon 1 of the
KRAS gene, ampliﬁed using a touchdown polymer-
ase chain reaction (PCR) cycle and hotstart protocol.
PCR products were initially puriﬁed and then directly
sequenced using BigDye version 3.1 dye terminators
and an ABI 3100 DNA fragment analyser. The
sequence at codon 12 and 13 was determined using
Mutation Surveyor (SoftGenetics, State College, PA,
USA) software.
BRAF mutation analysis at codon 600 (V600E;
formerly V599E) was performed by a real-time PCR-
based allelic discrimination method as previously
described.
29 Brieﬂy, real-time PCR was performed using
allele-speciﬁc primers designed to amplify selectively
the wild-type (T1796) and mutant (A1796) BRAF
alleles. The primer sequences were as follows: V,
5¢-GTGATTTTGGTCTAGCTACtGT;E ,5 ¢-CGCGGCCGG
CCGCGGCGGTGATTTTGGTCTAGCTACcGA; AS, 5¢-TA
GCCTCAATTCTTACCATCCAC. PCR ampliﬁcation and
melting curve analysis were performed on a Rotor-gene
3000 (Corbett Research, NSW, Australia). Genomic
DNA was ampliﬁed in a 15-ll volume containing 1 ·
Platinum SYBR Green qPCR SuperMix-UDG (Invitro-
gen, Carlsbad, CA, USA), forward primer V (300 nm),
forward primer E (900 nm) and reverse primer AS
(300 nm). The cycling conditions were as follows:
50 C for 2 min, 95 C for 2 min, 40 cycles of 95 C
for 15 s and 60 C for 60 s. After ampliﬁcation, samples
were subjected to a temperature ramp from 60 Ct o
99 C, rising 1 C each step. For wild-type samples,
single peaks were observed at 80 C while samples
containing mutant alleles produced single peaks at
85 C.
p53 immunohistochemistry and scoring
This was undertaken on all adenomas and all
serrated polyps with dysplasia (traditional SA and
MP). Most of these polyps had been immunostained
previously for MGMT.
24 Following deparafﬁnization
and rehydration of 4-lm sections and antigen
retrieval using ethylene diamine tetra-acetic acid
and microwaving, the sections were subjected to
peroxidase blockade (Dako EnVision bottle 1; Missi-
ssauga, Canada) and then incubated in 10% goat
serum to minimize non-speciﬁc staining. They were
subsequently incubated with the primary anti-p53
antibody (DO-7, from DakoCytomation, Mississauga,
Canada) at a dilution of 1 : 100 for 60 min at 37 C.
After washing, the sections were incubated with
secondary antibody (EnVision bottle 2) for 30 min,
washed again and then developed with the chromo-
gen AEC for 30 min. Finally, the sections were
counterstained with Gill’s haematoxylin. Polyps were
scored as showing loss of expression of MGMT if
there was complete absence of nuclear expression
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as positive for aberrant p53 expression if there were
distinct subclones characterized by strong nuclear
expression that implicated at least 50% of nuclei.
statistics
Data were analysed by v
2 test, Fisher’s exact test or
T-test, as appropriate, using SAS software, version 8.2
(Cary, NC, USA). P-values <0.05 were interpreted as
signiﬁcant.
Results
kras and braf mutation
DNAfailedtoamplifyintheKRASassayforoneSSAand
one TA <10 mm. Overall, 34 of 188 polyps (18%) had
mutation of KRAS. Twenty-eight mutations were in
codon 12 (20 GﬁA, seven GﬁT and one GﬁC) and six
mutations were in codon 13 (all GﬁA). One serrated
adenoma had two KRAS mutations in codon 12 (GﬁT
at position 35 and TﬁG at position 36). BRAF mutation
at V600E could be assessed in all polyps except for a
single TA <10 mm. BRAF mutation was found in 82 of
189 polyps (43%). BRAF and KRAS mutations were
negativelycorrelated, with only four polyps having both
mutations (two TAs, one TVA and one SSA). The three
conventional adenomas with mutations of both BRAF
and KRAS were among only four adenomas that had
any BRAF mutations at all. Mutation frequencies for
both KRAS and BRAF were distributed differently across
the seven polyp groups (Table 1).
KRAS mutation occurred in 26.5% and BRAF
mutation in 4.8% of adenomas (all types) (Table 1)
(P<0.0001). TVAs ⁄ VAs were more likely to have
KRAS mutation (50%) than TAs <10 mm (18%)
(P<0.004) or TAS >10 mm in diameter (17%)
(P<0.02). In the case of TAs there was a trend for
KRAS mutation to occur more frequently in polyps
from the proximal colon (P ¼ 0.08) and in females
(P ¼ 0.07).
SSAs were more likely to have BRAF mutation
(81%) than either SAs (33%) (P<0.001) or MPs
(40%) (P<0.02). KRAS mutation was infrequent
among both SSAs (3%) and HPs (4%) (Table 1).
Patient age, gender and anatomical location were not
predictors of BRAF mutation in either SSAs or HPs. The
mean age of subjects with SSAs (64 years) differed from
that of subjects with HPs (55 years) (P<0.001).
BRAF and KRAS mutations were distributed in
roughly similar proportions across MPs (90% had
either BRAF or KRAS mutation) and SAs (60% had
either BRAF or KRAS mutation) (Table 1). The fre-
quent ﬁnding of either BRAF or KRAS mutations
in both types of serrated polyp indicated that MPs and
SAs might be heterogeneous lesions. These 25 serrated
polyps with dysplasia were therefore grouped differ-
ently. Group A polyps (n ¼ 16) included a non-
dysplastic serrated component and ⁄ or dysplastic
epithelium in which the architectural and cytological
changes were more reminiscent of HP than adenoma
(Figure 1A,B). Group B polyps (n ¼ 9) comprised
serrated polyps in which the epithelial dysplasia
appeared adenomatous (Figure 1C,D). BRAF mutation
occurred in 10 ⁄ 16 Group A polyps but only 1 ⁄ 9 Group
Table 1. Frequency of
KRAS and BRAF mutation
and loss of expression of
O-6-methylguanine DNA
methyltransferase (MGMT)
by polyp type
Type of polyp KRAS mutation BRAF mutation MGMT loss
Hyperplastic polyp 2 ⁄ 49 (4%) 33 ⁄ 49 (67%) 6 ⁄ 42 (14%)
Sessile serrated adenoma 1 ⁄ 31 (3%) 26 ⁄ 32 (81%) 7 ⁄ 31 (23%)
Serrated adenoma 4 ⁄ 15 (27%) 5 ⁄ 15 (33%) 2 ⁄ 15 (13%)
Mixed polyp 5 ⁄ 10 (50%) 4 ⁄ 10 (40%) 7 ⁄ 9 (78%)
Tubular adenoma <10 mm 7 ⁄ 38 (18%) 2 ⁄ 38 (5%) 8 ⁄ 36 (22%)
Tubular adenoma >10 mm 4 ⁄ 23 (17%) 0 ⁄ 23 (0%) 11 ⁄ 20 (55%)
Adenoma with villosity 11 ⁄ 22 (50%) 2 ⁄ 22 (9%) 7 ⁄ 22 (32%)
Mutation frequencies for both KRAS (P<0.0001) and BRAF (P<0.0001) are distributed
differently across the seven classes of polyp (see Results for individual comparisons).
Distribution of MGMT loss differs across the seven classes of polyp (P<0.001).
Note: no result for KRAS in one sessile serrated adenoma (SSA) and one tubular adenoma (TA)
or for BRAF in one TA. MGMT immunstaining not performed in 15 polyps (seven HPs, one
SSA, one MP and six TAs).
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Figure 1. A, Serrated adenoma (SA) (BRAF mutation) with a ‘hyperplastic’ appearance but with architectural and cytological features of a non-
adenomatous form of dysplasia. The latter include marked epithelial serration and surface papillarity and nuclei that are ovoid, vesicular and
contain a prominent nucleolus (inset). The columnar cells (inset) contain apical mucin droplets, similar to sessile SA (SSA). B, Mixed polyp
(BRAF mutation) comprising SSA (left) and SA with high-grade dyplasia showing back-to-back glands (right) and aberrant expression of p53
(inset). C,D, Two mixed polyps (MPs) (both SA ⁄ tubulo-villous adenoma and with KRAS mutation) in which the serrated epithelium has an
adenomatous appearance as evidenced by elongated hyperchomatic nuclei with marked stratiﬁcation and a dark amphophilic cytoplasm. The
pure adenomatous component is not shown. E,F, Low- and medium-power images of a SA (KRAS mutation) in which complex microacini have
resulted in markedly serrated epithelial contours. The epithelium comprises numerous goblet cells and absorptive-type columnar cells with
eosinophilic cytoplasm and is reminiscent of the goblet cell variant of hyperplastic polyp. These examples illustrate the range of appearances and
genetic changes that are encompassed by ‘traditional’ SA.
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3 ⁄ 16 Group A polyps but in 5 ⁄ 9 Group B polyps (P ¼
0.06). In each of the ﬁve Group B polyps with KRAS
mutation, the adenomatous component showed both
villous change and serration.
With respect to the 25 serrated polyps with
dysplasia, only ﬁve occurred in the proximal colon
(up to the splenic ﬂexure). Two of these had BRAF
mutation (both Group A) and two had KRAS
mutation (both Group B). Seven of the 11 BRAF
mutations occurred in polyps derived from the left
colon or rectum (remaining two polyps with BRAF
mutation from site unknown). The three Group A
SAs with KRAS mutation (all from the left colon or
rectum) comprised numerous goblet cells and adjacent
cells with eosinophilic cytoplasm and no mucin pro-
duction or microvesicular appearance (Figure 1E,F).
These SAs therefore resembled the goblet cell variant
of HP.
loss of expression of mgmt
Loss of expression of MGMT was distributed differently
(P<0.001) across the different types of polyps, being
observed most frequently among MPs, TA >10 mm
and TVAs ⁄ VAs (Table 1). There was no correla-
tion between loss of expression of MGMT and either
KRAS or BRAF mutation across the full range of polyp
types. However, among TAs <10 mm, KRAS mutation
occurred in 3 ⁄ 25 (12%) adenomas with no MGMT
loss but in 4 ⁄ 8 (50%) adenomas with MGMT loss
(P<0.04). Since there were few KRAS mutations in
this subset and most KRAS mutations (5 ⁄ 7) were
GﬁA, it was not possible to demonstrate an association
between MGMT loss and GﬁA mutation in KRAS.
aberrant expression of p53 and correlation
with mgmt loss
Sixty-two TAs, 22 TVAs ⁄ VAs, 15 SAs and 10 MPs
were immunostained for p53. Weak expression of
nuclear p53 occurred frequently within the prolifera-
tive compartment in all types of polyps and was
ignored. Aberrant p53 expression was observed in
only four polyps: one TA, one MP (Figure 1B) and two
SAs (Figure 2). Overall, only 1 ⁄ 84 (1%) conventional
adenomas showed aberrant expression of p53 com-
pared with 3 ⁄ 25 (12%) serrated polyps with dysplasia
(P<0.04). In the latter, aberrant p53 expression
coincided with high-grade dysplasia and reduced or
complete loss of expression of MGMT (Figures 1B and
2). The TA with aberrant p53 expression had normal
expression of MGMT.
Discussion
The scientiﬁc basis for the prevention of cancer depends
upon an understanding of early events in pathogenesis,
including the mechanisms underlying initiation and
growth of precancerous polyps. Recommendations for
the management of patients with colorectal polyps
currently recognize only a single principal type of
C B A
Figure 2. High-power ﬁeld of a serrated adenoma with high-grade dysplasia (A) in which there is aberrant nuclear expression of p53 (B) and loss
of nuclear expression of O-6-methylguanine DNA methyltransferase (C).
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study includes additional types of polyp that are likely
to have malignant potential, namely serrated polyps
with (MP and SA) and without (SSA) dysplasia. This
discussion will focus ﬁrst on adenomas, second on non-
dysplastic serrated polyps and will then conclude with
the concept that features of these two types of polyp
can co-occur or become ‘fused’ in subtypes of advanced
polyps with mixed cytomorphology (hyperplastic and
dysplastic) and a serrated and ⁄ or villous architecture.
adenomas
The adenomas in this study were grouped as TAs
<10 mm, TAs >10 mm and TVAs ⁄ VAs. Overall,
KRAS mutation occurred in 26.5% of adenomas while
BRAF mutation was detected in only 4.8%. Three of
the four BRAF mutations occurred in adenomas that
also had KRAS mutation. It is well established that
BRAF and KRAS mutation rarely occur in the same
colorectal neoplasm.
12,16,30 Furthermore, BRAF muta-
tions are much more typical of serrated polyps than
adenomas.
14,31 The assay for BRAF mutation used in
this study was highly sensitive and it is possible that
the mutation was being identiﬁed in normal mucosa
included with the polyp. KRAS mutation may occur
within apparently normal colorectal mucosa and the
same could apply to BRAF.
32 Therefore, the ﬁnding of
BRAF mutation in a small subset of adenomas could be
spurious and the true incidence of BRAF mutation in
colorectal adenomas could be lower than 4.8%. BRAF
mutation frequencies of 0%
14 and 3%
31 have been
reported in other series of colorectal adenomas.
In previous studies of KRAS in colorectal adenomas,
mutation has been associated negatively with ﬂat and
depressed TAs and positively with polypoid appearance,
increasing size, dysplasia, villous change and syn-
chronous colorectal cancer.
6,33–35 In by far the largest
study, which included 738 adenomas obtained from
639 participants in a dietary intervention trial, multi-
variate analysis showed that the independent predic-
tors of KRAS mutation were age of subject, presence of
villous architecture and high-grade dysplasia, but not
size of adenoma.
6 It is well known that adenoma size,
dysplasia and villous architecture are interrelated and
account has to be taken of this in assessing results.
In this study KRAS mutation occurred with the same
frequency in small (18%) and large (17%) adenomas
but was signiﬁcantly more frequent in adenomas that
included a villous architecture (50%). A previous study
showed a very high frequency of KRAS mutation (93%)
in ﬂat adenomas with a tubulovillous architecture.
34
We would agree with the suggestion that KRAS
mutation is linked with the development of villous
change and does not inﬂuence adenoma growth in an
independent manner.
6 In this study, high-grade dys-
plasia was diagnosed only when it amounted to
carcinoma in situ. This was observed in none of the
84 adenomas but in four serrated polyps, of which
three showed aberrant expression of p53 and the
fourth had KRAS mutation. Age was not a predictor of
KRAS mutation in this study. However, many of the
patients were undergoing continuing colonoscopic
surveillance for colorectal polyps and it is known that
after clearance of large polyps, time is required for
the growth of newly initiated polyps.
36 This could
explain why adenomas were smaller in subjects aged
>60 years than in subjects aged <60 years (data not
shown).
non-dysplastic serrated polyps: hp and ssa
Non-dysplastic serrated polyps comprise conventional
HPs and the variant lesion which has been described as
SSA. In this study, SSAs accounted for approximately
3% of the overall series of polyps and were more age-
related than HPs. Importantly, SSAs have been linked
with the subset of colorectal cancer with BRAF
mutation, DNA methylation, MSI and serrated archi-
tecture.
14,18,37 In this study there was a high frequency
of BRAF mutation in conventional HPs (67%) as well
as in SSAs (81%). Previous reports have shown very
similar results for BRAF mutation in SSA,
16 but higher
frequencies of KRAS mutation and lower frequencies
of BRAF mutation in HPs.
12,16,38 As mentioned in
Materials and methods, there had been selection of
larger HPs in an earlier cell kinetic study involving the
same material. Large HPs are more likely to include
the subset described as ‘microvesicular’, in which the
columnar cells contain apical mucin droplets within
small vesicles while goblet cells are rendered inconspi-
cuous.
25 BRAF mutation occurs more frequently in the
microvesicular variant of HP.
16 By contrast, KRAS
mutation occurs much more commonly in the goblet
cell variant of HP, which is usually small, located in
the left colon or rectum and deviates minimally from
normal colorectal mucosa in terms of differentiation
and architecture.
16,25 The latter were under-represen-
ted in this series (details not shown).
dysplastic serrated polyps: mp and sa
Serrated polyps with dysplasia, i.e. MPs and SAs,
together comprised only 2% of the overall consecutive
series of 1250 polyps. While mutation of KRAS and
BRAF was associated with conventional adenoma
Colorectal polyps 127
  2006 The Authors. Journal compilation   2006 Blackwell Publishing Ltd, Histopathology, 49, 121–131.and SSA, respectively (see above), BRAF and KRAS
mutation occurred with similar frequency in both MPs
(40% and 50%, respectively) and SAs (33% and 27%,
respectively). In the literature, the frequency of BRAF
and KRAS mutation in MP or SA has ranged from 36 to
100% and from 0% to 60%, respectively.
12,16,39–42
These ﬁndings indicate that this subset of colorectal
polyps is likely to be heterogeneous in terms of its
molecular origins. These polyps were therefore reclas-
siﬁed according to their resemblance to HP or SSA
(Group A) (Figure 1A,B,E,F) or to conventional aden-
oma (Group B) (Figure 1C,D). Particular histological
features among the Group A polyps were: marked
serration, a papillary or villous architecture, a relat-
ively abundant eosinophilic cytoplasm, columnar cells
with apical mucin droplets, nuclei that were enlarged,
ovoid, vesicular and contained a prominent nucleolus,
and adjacent non-dysplastic serrated polyp. Particular
histological features among the Group B polyps were:
some glandular serration, frequent villous change and
epithelial dysplasia that appeared adenomatous (cyto-
plasmic basophilia and nuclei that were elongated,
pseudostratiﬁed and hyperchromatic without a prom-
inent nucleolus). Importantly, BRAF mutation occur-
red more frequently among Group A polyps (P<0.03),
whereas there was a trend for KRAS to be more
frequent among Group B polyps (P ¼ 0.06).
The preceding ﬁndings indicate that serrated polyps
with dysplasia evolve through at least two independent
histogenetic pathways. Group A polyps are likely to be
initiated by BRAF mutation and are serrated lesions at
the outset. Group B polyps may begin as conventional
adenomas and then become serrated and villous
following mutation of KRAS. There may be instances
in which KRAS mutation can initiate lesions which are
serrated at the outset and become dysplastic. While this
suggestion remains speculative, it may apply to the
Group A serrated polyps that show a distinct likeness to
the goblet cell variant of HP in which columnar cells
are eosinophilic and lack mucin-ﬁlled microvesicles
and KRAS mutation is frequent (Figure 1E,F).
16,25 The
literature refers to the concept of ‘traditional’ SA.
43
Based on the current ﬁndings, it is likely that several
mechanisms can account for adenomatous lesions with
glandular serration and that ‘traditional’ SA is not a
single entity.
concept of ‘fusion’ pathways to crc
Colorectal polyps have traditionally been classiﬁed into
distinct histogenetic types that may progress to CRC
through independent pathways of colorectal tumori-
genesis (Table 2). However, in addition to the two
‘classical’ pathways to CRC shown in Table 2, there
may be ‘fusion’ pathways that combine mechanisms
associated with both adenomas and serrated polyps.
This would explain why many CRCs display pheno-
types associated with serrated polyps as well as
adenomas.
44 Three possible examples of such fusion
pathways are shown in Table 3. It is difﬁcult to observe
directly the actual point of transition from benign to
malignant colorectal lesions. Once the key rate-limiting
step is achieved it is likely that the transition to cancer
occurs rapidly and the precursor lesion is then over-
taken by the malignancy. Changes leading to inacti-
vation of either TP53
5 or the DNA mismatch repair
gene MLH1
13 are likely to be two such rate-limiting
mechanisms. Only a single instance of loss of expres-
sion of MLH1 was observed in the present series of
polyps and the adenoma in question was inferred to be
from a patient with Lynch syndrome.
24
The interpretation of immunostaining for p53 is
problematic insofar as increased expression of the wild-
type protein occurs in areas of increased proliferation
and must be distinguished from the diffuse and strong
nuclear staining associated with retained mutant
protein. However, several studies have described low
frequencies of p53 expression in TAs with low-grade
dysplasia
45,46 and even in VAs.
47 Conversely, there is
general agreement that aberrant p53 expression is
closely associated with the presence of high-grade
dysplasia amounting to carcinoma in situ.
34,46,48
Aberrant retention of presumed mutant nuclear p53
was rarely observed in the present series, although
Table 2. Concept of dis-
crete colorectal lesions and
progression to colorectal
cancer via independent
pathways
Initiation Lesions Methylation Progression Instability ⁄ ploidy
KRAS ACF and HP + Rare Not applicable
BRAF SSA and SA +++ MLH1* Microsatellite ⁄ diploid
APC TA + ⁄ – TP53* Chromosomal ⁄ aneuploid
ACF, Aberrant crypt foci (hyperplastic or dysplastic); HP, hyperplastic polyp; SSA, sessile
serrated adenoma; SA, serrated adenoma; TA, tubular adenoma.
*Inactivation of MLH1 and TP53 is associated with malignant progression.
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dysplasia (12%) than in adenomas (1%). One of the
polyps with aberrant expression of p53 was a mixed
polyp with BRAF mutation (Figure 1B). Had it not
been removed, this polyp may have progressed within a
short time frame to the subset of CRC with BRAF
mutation, DNA methylation, TP53 mutation and DNA
microsatellite stable status (a ‘fusion’ pathway shown
in Table 3).
49,50
Loss of expression of the DNA repair gene MGMT
is associated with methylation of the promoter
region
45,51,52 and the latter change has been linked
causatively with G:C to A:T transition mutations in
TP53.
53 In the present study, complete or partial loss
of expression of MGMT coincided with aberrant
nuclear expression of p53 in three serrated polyps
with dysplasia (Figure 2), but not in the single
tubular adenoma with aberrant p53 expression. Only
one previous study has attempted to correlate MGMT
and p53 expression in colorectal polyps.
45 In that
study, 4.3% of adenomas showed aberrant p53
expression but none had loss of MGMT. It is possible
that the link between MGMT silencing and TP53
mutation is more evident in the serrated pathway
than in the adenoma–carcinoma sequence. The fre-
quency of TP53 mutation in SAs has ranged from
5 to 50% in the literature.
39,41,54 Although a link
between MGMT loss and aberrant expression of p53
is supported by the present ﬁndings, it should be
noted that only a small number of polyps showed
these changes concurrently.
KRAS mutation has been linked to the initiation of
hyperplastic aberrant crypt foci and small HPs
7,38,55
and is therefore closely associated with the develop-
ment of glandular serration. While the acquisition of
KRAS mutation is also observed in adenomas, this
change is correlated with the development of a villous
architecture and in some cases the presence of epithe-
lial serration (see Discussion of Group B serrated polyps
above). It may therefore be conceptually correct to view
KRAS mutation as adding a serrated molecular signa-
ture to the traditional adenoma and hence providing
an additional ‘fusion’ pathway. However, a mechanis-
tic link between KRAS mutation and the morpho-
genesis of serration and villous change remains to be
established. MGMT is again implicated in this second
type of ‘fusion’ since methylation and inactivation of
this DNA repair gene has been linked to G:C to A:T
transitions in KRAS.
56–58 In this study there was an
association between loss of expression of MGMT and
KRAS mutation among small TAs (P ¼ 0.04) but not
in the other polyp categories. Methylation of MGMT
occurs in normal colorectal mucosa,
59 as well as in
polyps, and is therefore unlikely to serve as a key rate-
limiting step in the transition to malignancy. A possible
third ‘fusion’ pathway implicating KRAS and methyla-
tion of APC
60 is included in Table 3.
In summary, MPs and SAs account for only about
2% of colorectal polyps. Nevertheless, those serrated
polyps with dysplasia show frequent mutation of either
KRAS or BRAF and frequent loss of expression of
MGMT (particularly MP). Additionally, four of 25 (16%)
showed high-grade dysplasia and in three of these there
was concordant aberrant nuclear expression of p53.
Along with SSAs, these rare polyps may serve as the
precursors of sporadic CRCs with BRAF mutation and
DNA methylation (with and without DNA MSI) and a
subset of CRCs with KRAS mutation. Their malignant
potential is explained by the accumulation of genetic
alterations that may in turn depend upon the inactiva-
tion of the DNA repair gene MGMT.
28 The importance
of these ‘fusion’ polyps as cancer precursors may be
under-appreciated because critical rate-limiting chan-
ges governing malignant transition, particularly in
association with loss of function of MLH1 of p53, occur
rapidly and can rarely be ‘caught in the act’.
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Table 3. ‘Fusion’ pathways
brought about by the seq-
uential alteration of genes
(linked to separate lesions
and pathways in Table 2)
and with the second alter-
ation associated with a
superimposed morphology
Fusion Mechanism Superimposed morphology Instability
BRAF-TP53 Methylation MGMT Dysplasia on serration Various ⁄ subtle*
APC-KRAS Methylation MGMT Villosity on adenoma Various ⁄ subtle*
KRAS-APC Methylation APC Dysplasia on serration Various ⁄ subtle*
*MGMT inactivation predisposes to G:T mismatches and chromosomal instability through
futile cycles of excision and repair as well as to mutation of KRAS and TP53.
9 Partial
methylation of MLH1 may also lead to low-level microsatellite instability.
37
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